Flow Diversion Aneurysm Treatment Market size is set to grow by USD 2.43 billion from 2024-2028, Increasing incidence of intracranial aneurysms boost the market, Technavio
NEW YORK, June 24, 2024 /PRNewswire/ -- The global flow diversion aneurysm treatment market size is estimated to grow by USD 2.43 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of 9.34% during the forecast period. The flow diversion aneurysm treatment market is booming due to the rising prevalence of intracranial aneurysms and the growing popularity of minimally invasive treatments.
Research report provides comprehensive data on impact of trend. For more details- Download a Sample Report
Here's a quick breakdown of the key drivers and challenges in this market:
Market Drivers:
Increasing awareness and diagnosis of intracranial aneurysms: More people are being diagnosed with aneurysms, thanks to better imaging techniques and public health campaigns.
Minimally invasive nature of flow diversion procedures: Compared to traditional brain surgery, flow diversion offers a less risky and quicker recovery time for patients.
Improved patient outcomes: Flow diverters effectively redirect blood flow away from the aneurysm, promoting clot formation and preventing rupture.
Market Challenges:
Stringent regulatory hurdles: Getting flow diverter devices approved by regulatory bodies like the FDA can be a lengthy and expensive process.
High cost of treatment: Flow diversion procedures can be expensive, limiting access for some patients. Lack of proper reimbursement policies in certain regions further restricts affordability.
Procedural complexity: Flow diversion requires highly skilled surgeons and specialized equipment, which may not be readily available in all hospitals.
Market Players and Products:
Major players in this market include companies like Stryker, Medtronic, and MicroVention who develop and manufacture flow diverter devices. These devices come in various types, with FDS (Flow Diversion Stents) being the most common.
Market Outlook:
Despite the challenges, the flow diversion aneurysm treatment market is expected to continue growing due to rising patient demand, technological advancements, and increasing awareness about this minimally invasive treatment option.
About Technavio
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Barrington James, a global leader in Life Science Recruitment, proudly announces the acquisition of S3 Science Recruitment, a firm renowned for its expertise in drug discovery, medical research, and the broader field of life sciences. Terms of the...
July 3, 2024 Amsterdam, the Netherlands ? Royal Philips , a global leader in health technology, today announced the appointment of Ms Ling Liu as the Chief Region Leader of Philips Greater China, effective immediately. Ms Liu is now a member of...
Hansa Biopharma, "Hansa" , will publish its interim report for January-June 2024 on July 18, 2024. Interested parties may join the Company's quarterly conference call on the same date at 14:00 CEST/8:00 AM EST. The event will be hosted by Søren...
Regulatory News:
BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced artificial intelligence (AI) to accelerate biopharma drug discovery, today announces a change to its Executive Leadership Team...
In the news release, AbbVie, Inc.'s Zymaxid tm Implicated in Product Liability Lawsuit Due to Risk of Serious Injury and Death, issued 02-Jul-2024 by Wormington & Bollinger over PRWeb, the source of the release should be "Wormington & Bollinger"...
Author David W. Treaster shares a Christian-based plan that can supplement a cancer patient's medical treatment plan in God Power Cancer Healing Plan: Spiritual Component ($15.99, paperback, 9781662899942; $7.99, e-book, 9781662899959).
As long as...